Ishita Drugs & Indus Intrinsic Value
ISHITADR Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹70.40 | ₹56.32 - ₹84.48 | -8.0% | EPS: ₹3.20, Sector P/E: 22x |
| Book Value Method | asset | ₹73.33 | ₹66.00 - ₹80.66 | -4.2% | Book Value/Share: ₹36.67, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹120.00 | ₹108.00 - ₹132.00 | +56.8% | Revenue/Share: ₹60.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹66.67 | ₹60.00 - ₹73.34 | -12.9% | EBITDA: ₹2.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹61.89 | ₹49.51 - ₹74.27 | -19.1% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹22.96 | ₹20.66 - ₹25.26 | -70.0% | EPS Growth: 4.4%, Fair P/E: 3.5x |
| Growth Adjusted P/E | growth | ₹49.56 | ₹44.60 - ₹54.52 | -35.2% | Revenue Growth: 6.5%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹38.27 | ₹34.44 - ₹42.10 | -50.0% | ROE: 9.1%, P/E Multiple: 10x |
| Graham Defensive Method | conservative | ₹51.38 | ₹46.24 - ₹56.52 | -32.9% | EPS: ₹3.20, BVPS: ₹36.67 |
Want to compare with current market value? Check ISHITADR share price latest .
Valuation Comparison Chart
ISHITADR Intrinsic Value Analysis
What is the intrinsic value of ISHITADR?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Ishita Drugs & Indus (ISHITADR) is ₹61.89 (median value). With the current market price of ₹76.54, this represents a -19.1% variance from our estimated fair value.
The valuation range spans from ₹22.96 to ₹120.00, indicating ₹22.96 - ₹120.00.
Is ISHITADR undervalued or overvalued?
Based on our multi-method analysis, Ishita Drugs & Indus (ISHITADR) appears to be trading above median value by approximately 19.1%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Debt to Equity Ratio | 1.45 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | 9.1% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 7.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.12x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
Related Pages for Ishita Drugs & Indus
Additional stock information and data for ISHITADR
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-4 Cr | ₹-5 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹2 Cr | ₹2 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹-3 Cr | ₹-3 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹3 Cr | ₹3 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹-1 Cr | ₹-1 Cr | Negative Cash Flow | 3/10 |